Retatrutide

InvestigationalMetabolic ResearchWeight & metabolicLongevity & cellular
5.6

Neutral, BioHarmony verdict

BioHarmony score 5.6 out of 10

Retatrutide is Lilly's investigational once-weekly GLP-1/GIP/glucagon triple agonist. Jastreboff 2023 reported up to 24.2% body-weight loss at 48 weeks, but FDA says retatrutide is not approved and cannot legally be compounded.

Read full report

What is Retatrutide?

Retatrutide is an investigational once-weekly peptide drug from Eli Lilly that activates three metabolic hormone receptors at once: GLP-1R, GIPR, and glucagon receptor. In practice, that means appetite suppression, improved insulin signaling, and a glucagon-driven push toward hepatic fat oxidation and thermogenesis in the same molecule. This is why retatrutide sits beyond semaglutide and tirzepatide in pharmacological ambition.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Simultaneous agonism of GLP-1, GIP, and glucagon receptors; the glucagon arm is intended to raise hepatic fat oxidation and energy expenditure while GLP-1/GIP constrain appetite and improve glycemia.

Safety watch-outs

  • Persistent vomiting or dehydration
  • Severe abdominal pain
  • Blood in stool or black stool
  • Symptoms of pancreatitis: severe upper abdominal pain radiating to back

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Retatrutide yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (3)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingCannot be used in compounding under US federal law

FDA states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.